Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Cancer Transcriptome-Based Resolution of Isoform Complexity by Pacific Biosciences Fusion and Long Isoform Pipeline

Tyler Jacobs

Short-read sequencing for genomic profiling is useful for identifying disease-related variation in both DNA and RNA. However, molecular profiling utilising long-read sequencing enhances the resolution of such events because structural variation in cancer occurs often. For instance, the Pacific Biosciences long-read RNA-sequencing (Iso-Seq) transcriptome technique finds expressed fusion partners and offers full-length isoform characterisation, discernment of allelic phasing, and isoform identification. To find expressed fusion partners and isoforms, the Pacific Biosciences Fusion and Long Isoform Pipeline (PB FLIP) uses a variety of RNA-sequencing software analysis tools and scripts. In order to test our methodology and analytical performance, sequencing of a commercial reference (Spike-In RNA Variants) with known isoform complexity was carried out. This sequencing showed strong recall of the Iso-Seq and PB FLIP workflow. This work explains how Iso-Seq and PB FLIP analysis can help with isoform recognition and difficult structural variant deconvolution in a cohort of institutional paediatric and adolescent/young adult cancer research participants. The exemplary case studies show that Iso-Seq and PB FLIP can distinguish between allele-specific expression patterns, resolve complex intragenic changes, and find novel expressed fusion partners.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié.